ABSTRACT

Oncolytic virus therapy (OVT), a form of immunotherapy, is based on the use of genetically engineered viruses that selectively infect cancerous cells; produce progeny which are capable of lysing the infected malignant cells as well as elicit a systemic anti-tumor immune response. Advances in molecular virology, synthetic biology, and immuno-oncology have allowed for significant improvements in the tumor specificity, safety, and efficacy of all forms of oncolytic viral systems. This review will discuss the various mechanisms by which OVT achieves tumor cell selectivity, methods of genetic modification for enhancing the therapeutic potential of these systems, how they modulate the tumor microenvironment (TME), their current clinical applications, their application in combination with other therapeutic modalities, their limitations, the development of biomarkers for monitoring the therapeutic response and emerging technologies being developed for translation into the clinic through 2026.

KEYWORDS

Oncolytic viruses; Cancer immunotherapy; Tumor microenvironment; Genetic engineering; HSV-1; Adenovirus; CRISPR; Immune checkpoint inhibitors

REFERENCES

1) Malfitano, A.M. ∙ Di Somma, S. ∙ Iannuzzi, C.A.Virotherapy: From single agents to combinatorial treatments Biochem. Pharmacol. 2020; 177, 113986
2) Russell, S.J. ∙ Barber, G.N.Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines Cancer Cell. 2018; 33:599-605
3) Letafati, A. ∙ Ardekani, O.S. ∙ Naderisemiromi, M.Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications Virol. J. 2024; 21:18
4) Banete, A. ∙ Barilo, J. ∙ Whittaker, R.The Activated Macrophage – A Tough Fortress for Virus Invasion: How Viruses Strike Back Front. Microbiol. 2021; 12, 803427
5) Bhatt, D.K. ∙ Chammas, R. ∙ Daemen, T. Resistance mechanisms influencing oncolytic virotherapy, a systematic analysis Vaccines. 2021; 9, 1166
6) Macedo, N. ∙ Miller, D.M. ∙ Haq, R.Clinical landscape of oncolytic virus research in 2020 J. Immunother. Cancer. 2020; 8, e001486
7) van Schaik, T.A. ∙ Moreno-Lama, L. ∙ Aligholipour Farzani, T.Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors Biomed. Pharmacother. 2023; 162, 114665
8) Ma, R. ∙ Lu, T. ∙ Li, Z.An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma Cancer Res. 2021; 81:3635-364
9) Cui, C. ∙ Wang, X. ∙ Lian, B.OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study J. Immunother. Cancer. 2022; 10, e004307
10) Danson, S.J. ∙ Conner, J. ∙ Edwards, J.G.Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716 Lung Cancer. 2020; 150:145-151
11) Robert, C. ∙ Gastman, B. ∙ Gogas, H.Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115 Eur. J. Cancer. 2024; 207, 114120
12) Dummer, R. ∙ Gyorki, D.E. ∙ Hyngstrom, J.Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial Nat. Med. 2021; 27:1789-1796
13) Monga, V. ∙ Miller, B.J. ∙ Tanas, M.Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial J. Immunother. Cancer. 2021; 9, e003119
14) Malvehy, J. ∙ Samoylenko, I. ∙ Schadendorf, D.Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma J. Immunother. Cancer. 2021; 9, e001621
15) Soliman, H. ∙ Hogue, D. ∙ Han, H.A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer Clin. Cancer Res. 2021; 27:1012-1018
16) Monge, C. ∙ Xie, C. ∙ Myojin, Y.Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer J. Immunother. Cancer. 2023; 11, e005640
17) Chintala, N.K. ∙ Choe, J.K. ∙ McGee, E.Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma Front. Immunol. 2023; 14, 1112960
18) Toulmonde, M. ∙ Cousin, S. ∙ Kind, M.Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma J. Hematol. Oncol. 2022; 15:149
19) Toulmonde, M. ∙ Guegan, J.-P. ∙ Spalato-Ceruso, M.the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamideMol. Cancer. 2024; 23:38
20) Manyam, M. ∙ Stephens, A.J. ∙ Kennard, J.A.A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer Gynecol. Oncol. 2021; 163:481-489.

Cite this article :

Al-Kinani, R. M. H., Obaid, K., & Alshammary, Z. B. (2026). Oncolytic Virotherapy in Cancer Treatment. INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, 5(3), 231-235. https://doi.org/10.58806/ijhmr.2026.v5i3n08